HealthEquity (NASDAQ: HQY) reported Q3 EPS of $0.35, in-line with the analyst estimate of $0.35. Revenue for the quarter came in at $180 million versus the consensus estimate of $185.05 million.

GUIDANCE:

HealthEquity sees FY2022 EPS of $1.30-$1.35, versus the consensus of $1.48. HealthEquity sees FY2022 revenue of $750-755 million, versus the consensus of $762.3 million.

• For the fiscal year ending January 31, 2022, management expects revenues of $750 million to $755 million. Its outlook for net loss is between $36 million and $33 million, resulting in net loss of $0.43 to $0.40 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $108 million and $112 million, resulting in non-GAAP net income per diluted share of $1.30 to $1.35 (based on an estimated 83 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $230 million to $235 million. This outlook includes the impact of the Fifth Third Bank HSA portfolio, which closed on September 29, 2021, and the Further acquisition, which closed on November 1, 2021. This outlook also includes the impact of the $600 million aggregate principal amount of 4.50% Senior Notes due 2029 and the refinanced credit facility.

For earnings history and earnings-related data on HealthEquity (HQY) click here.